Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Alcohol withdrawal prevention: a randomized evaluation of lorazepam and ethanol--a pilot study.

Publication ,  Journal Article
Fullwood, JE; Mostaghimi, Z; Granger, CB; Washam, JB; Bride, W; Zhao, Y; Granger, BB
Published in: Am J Crit Care
September 2013

BACKGROUND: Alcohol withdrawal syndrome, characterized by confusion, agitation, and hallucinations, decreases the safety of patients with acute myocardial infarction. Unexpected hospitalization and sudden cessation of alcohol consumption may increase in-hospital complications and length of stay and even precipitate death. PURPOSE: To perform a randomized evaluation of lorazepam and ethanol/lorazepam to evaluate the safety and efficacy of these 2 strategies for preventing alcohol withdrawal syndrome in patients with acute coronary syndromes. METHODS: Patients (n = 57) with myocardial infarction were screened for alcohol dependence by using the CAGE questionnaire and randomized to treatment with lorazepam or ethanol with lorazepam. Demographics and complication rates were analyzed by using χ² tests (categorical variables) and t tests (continuous variables). Safety (composite complication rates) of the treatment strategy was evaluated by using the Fisher exact test, and length of stay by using the Wilcoxon rank-sum test. RESULTS: Safety-associated complication rates (self-extubation, delirium tremens, reinfarction) did not differ between groups (24% lorazepam vs 18% ethanol; P = .56). Days spent in the cardiac intensive care unit (7% lorazepam vs 2% ethanol; P = .32) and overall hospital stay (6% lorazepam vs 6% ethanol; P = .72) did not differ between the 2 groups. CONCLUSIONS: These preliminary findings suggest that a randomized evaluation of treatment strategies to prevent complications associated with alcohol withdrawal in patients with acute myocardial infarction is safe and feasible.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am J Crit Care

DOI

EISSN

1937-710X

Publication Date

September 2013

Volume

22

Issue

5

Start / End Page

398 / 406

Location

United States

Related Subject Headings

  • Substance Withdrawal Syndrome
  • Prospective Studies
  • Pilot Projects
  • Nursing
  • Middle Aged
  • Male
  • Lorazepam
  • Length of Stay
  • Intensive Care Units
  • Hypnotics and Sedatives
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fullwood, J. E., Mostaghimi, Z., Granger, C. B., Washam, J. B., Bride, W., Zhao, Y., & Granger, B. B. (2013). Alcohol withdrawal prevention: a randomized evaluation of lorazepam and ethanol--a pilot study. Am J Crit Care, 22(5), 398–406. https://doi.org/10.4037/ajcc2013283
Fullwood, Joyce E., Zhila Mostaghimi, Christopher B. Granger, Jeffrey B. Washam, Wanda Bride, Yanfang Zhao, and Bradi B. Granger. “Alcohol withdrawal prevention: a randomized evaluation of lorazepam and ethanol--a pilot study.Am J Crit Care 22, no. 5 (September 2013): 398–406. https://doi.org/10.4037/ajcc2013283.
Fullwood JE, Mostaghimi Z, Granger CB, Washam JB, Bride W, Zhao Y, et al. Alcohol withdrawal prevention: a randomized evaluation of lorazepam and ethanol--a pilot study. Am J Crit Care. 2013 Sep;22(5):398–406.
Fullwood, Joyce E., et al. “Alcohol withdrawal prevention: a randomized evaluation of lorazepam and ethanol--a pilot study.Am J Crit Care, vol. 22, no. 5, Sept. 2013, pp. 398–406. Pubmed, doi:10.4037/ajcc2013283.
Fullwood JE, Mostaghimi Z, Granger CB, Washam JB, Bride W, Zhao Y, Granger BB. Alcohol withdrawal prevention: a randomized evaluation of lorazepam and ethanol--a pilot study. Am J Crit Care. 2013 Sep;22(5):398–406.

Published In

Am J Crit Care

DOI

EISSN

1937-710X

Publication Date

September 2013

Volume

22

Issue

5

Start / End Page

398 / 406

Location

United States

Related Subject Headings

  • Substance Withdrawal Syndrome
  • Prospective Studies
  • Pilot Projects
  • Nursing
  • Middle Aged
  • Male
  • Lorazepam
  • Length of Stay
  • Intensive Care Units
  • Hypnotics and Sedatives